Insilico Medicine
Healthcare AI
Drug discovery and development using generative AI
Public
Insilico Medicine is a global, clinical-stage biotechnology company that uses **generative AI** and automation to power end-to-end drug discovery and development, integrating genomics, biology, chemistry, and clinical trial analysis through its proprietary Pharma.AI platform to design novel therapeutics for oncology, fibrosis, immunology, CNS, infectious and aging-related diseases. The company is publicly listed on the Hong Kong Stock Exchange (HKEX: 3696) and is recognized for advancing one of the first generative AI-discovered and AI-designed drug candidates into human clinical trials.
Company Details
- Website
- insilico.com
- Headquarters
- Boston/Cambridge, Massachusetts, United States
- Founded
- 2014
- Funding
- $510M
Subscriber Intelligence
- • Deal signal alerts for this company
- • Sentiment & risk scoring
- • Competitive framework analysis
- • Regulatory event monitoring